ONL Therapeutics
Ann Arbor, US · Founded 2011 · Delaware corporation · 10 known investors
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness. Its lead candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide targeting Fas-mediated signaling across multiple eye diseases.
BiotechHealthtechMedical Devices
Founders & leadership
ONL Therapeutics was founded in 2011 by David Zacks.
DZ
David ZacksCo-Founder & Chief Scientific Officer
DE
David EspositoExecutive
CC
Constance ChangExecutive
JK
John K FreshleyExecutive
JA
Jeffrey A JamisonNamed on SEC filing
DN
David N ZacksNamed on SEC filing
Board
AF
MS
MN
WB
William BrinkerhoffBoard director
BB
Bill BurnsBoard director
LC
Loic CouraudBoard director
Investors · 10
ExSight Ventures✓ verifiedNew York
Invest Michigan✓ verifiedNorthville · $100K – $250K
Novartis Venture Fund✓ verifiedBasel · $5M – $25M
Visionary Ventures✓ verifiedNewport Beach · $5M – $15M
Bios Partners✓ verifiedFort Worth
InFocus Capital Partners, LLC✓ verifiedJericho
Johnson & Johnson Innovation – JJDC✓ verifiedNew Brunswick
Michigan Capital NetworkGrand Rapids
OphthaFundCharlestonvia Tom Mather · inferred
WMU Biosciences Research & Commercialization CenterKalamazoo · $100K – $250K
Reported raises · per SEC filings
Form D private placements$111.5M disclosed across 10 rounds · 2014–2024
▶$60MraisedSep 2024 · 35 investors · BiotechnologyRule 506(b)
▶$60MraisedSep 2024 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David EspositoExecutive Officer, Director
- Constance ChangExecutive Officer
- Aaron FletcherDirector
- Michal SilverbergDirector
- Bill BurnsDirector
- David ZacksExecutive Officer
- Marian NakadaDirector
- Offering amount
- $65M
- Amount sold
- $60M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedMar 2024 · 35 investors · BiotechnologyRule 506(b)
▶$10MraisedMar 2024 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David EspositoExecutive Officer, Director
- Constance ChangExecutive Officer
- Bill BurnsDirector
- David ZacksExecutive Officer, Director
- Stella RobertsonDirector
- Mark HooperDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMar 2023 · 30 investors · BiotechnologyRule 506(b)
▶$5MraisedMar 2023 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bill BurnsDirector
- Constance ChangExecutive Officer
- David EspositoExecutive Officer, Director
- Mark HooperDirector
- David ZacksExecutive Officer, Director
- Stella RobertsonDirector
- Offering amount
- $15M
- Amount sold
- $5M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$26.8MraisedDec 2020 · 44 investors · BiotechnologyRule 506(b)
▶$26.8MraisedDec 2020 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bill BurnsDirector
- Stella RobertsonDirector
- David EspositoExecutive Officer, Director
- Mark HooperDirector
- David ZacksExecutive Officer, Director
- Offering amount
- $47.4M
- Amount sold
- $26.8M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedOct 2020 · 3 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David EspositoExecutive Officer, Director
- Felicia David-VisserDirector
- Christine GibbonsDirector
- Mark HooperDirector
- David ZacksExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedAug 2019 · 25 investors · BiotechnologyRule 506(b)
▶$3MraisedAug 2019 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ZacksExecutive Officer, Director
- Mark HooperDirector
- Christine GibbonsDirector
- Felicia David-VisserDirector
- David EspositoExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$639KraisedSep 2018 · 14 investors · BiotechnologyRule 506(b)
▶$639KraisedSep 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John FreshleyExecutive Officer, Director
- Felicia David-VisserDirector
- Christine GibbonsDirector
- Mark HooperDirector
- David ZacksExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $639K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedMay 2017 · 19 investors · BiotechnologyRule 506(b)
▶$2.6MraisedMay 2017 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rafael CastillaDirector
- David ZacksExecutive Officer, Director
- John FreshleyExecutive Officer, Director
- Christine GibbonsDirector
- Mark HooperDirector
- Offering amount
- $4.3M
- Amount sold
- $2.6M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapEledon7 shared keywordsEledon develops tegoprubart, an anti-CD40L antibody in clinical development for preventing rejection in organ transplant recipients. The company focuses on improving long-term graft survival and quality of life for transplant recipients across kidney, liver, and xenotransplantation.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with ONL Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2020 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $300.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $421.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does ONL Therapeutics do?
- ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness. Its lead candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide targeting Fas-mediated signaling across multiple eye diseases.
- Who founded ONL Therapeutics?
- ONL Therapeutics was founded by David Zacks in 2011.
- Who are ONL Therapeutics's investors?
- ONL Therapeutics's investors include ExSight Ventures, Invest Michigan, Novartis Venture Fund, Visionary Ventures, Bios Partners, InFocus Capital Partners, LLC, Johnson & Johnson Innovation – JJDC, Michigan Capital Network and 2 more.
- How much funding has ONL Therapeutics raised?
- ONL Therapeutics has disclosed $111.5M raised across 10 rounds.
- Where is ONL Therapeutics headquartered?
- ONL Therapeutics is headquartered in Ann Arbor, US.